Medulloblastoma – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Medulloblastoma - Pipeline Review, H1 2012', provides an overview of the Medulloblastoma therapeutic pipeline. This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medulloblastoma. 'Medulloblastoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Medulloblastoma.
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Medulloblastoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Medulloblastoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medulloblastoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medulloblastoma 7
Medulloblastoma Therapeutics under Development by Companies 9
Medulloblastoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Medulloblastoma Therapeutics – Products under Development by Companies 17
Medulloblastoma Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Medulloblastoma Therapeutics Development 20
Eli Lilly and Company 20
Novartis AG 21
Pfizer Inc. 22
Archer Biosciences, Inc 23
Medulloblastoma – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Zactima + Isotretinoin - Drug Profile 30
Alimta - Drug Profile 31
Gemcitabine + Oxaliplatin - Drug Profile 33
GW572016 - Drug Profile 35
LDE225 - Drug Profile 36
Irinotecan + Temozolomide - Drug Profile 37
Bevacizumab + Camptosar - Drug Profile 38
Torisel - Drug Profile 39
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile 40
Etoposide + Filgrastim + Cisplatin + Cyclophosphamide + Vincristine sulfate + Radiation Therapy - Drug Profile 43
Cisplatin + Cyclophosphamide + Etoposide + Lomustine + Vincristine + Radiation Therapy - Drug Profile 45
Verteporfin - Drug Profile 47
Carboplatin + Cisplatin - Drug Profile 48
LEQ506 - Drug Profile 49
Dendritic cells + Imiquimod - Drug Profile 50
Cyclophosphamide + Etoposide + Cisplatin + Vincristine + Thiotepa + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 51
Cyclophosphamide + Vincristine Sulfate - Drug Profile 53
Cisplatin + Lomustine + Vincristine Sulfate - Drug Profile 54
ARC-100 + Temodar - Drug Profile 56
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile 58
ABT-888 + Temozolomide - Drug Profile 60
Irinotecan + Temozolomide - Drug Profile 61
Isotretinoin + Vorinostat - Drug Profile 62
Isotretinoin + Vorinostat - Drug Profile 63
Tipifarnib - Drug Profile 64
Temozolomide + Irinotecan + Bevacizumab - Drug Profile 65
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile 66
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile 68
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile 70
Nifurtimox + Cyclophosphamide + Topotecan - Drug Profile 72
Temozolomide + Etoposide - Drug Profile 74
TTRNA-xALT + TTRNA-DCs - Drug Profile 75
Siomycin A - Drug Profile 77
Medulloblastoma Therapeutics – Drug Profile Updates 78
Medulloblastoma Therapeutics - Dormant Products 79
Medulloblastoma – Product Development Milestones 81
Featured News & Press Releases 81
Appendix 83
Methodology 83
Expert Panel Validation 84
Contact Us 84
Disclaimer 84
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Medulloblastoma, H1 2012 10
Products under Development for Medulloblastoma – Comparative Analysis, H1 2012 11
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 14
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2012 16
Comparative Analysis by Mid Clinical Stage Development, H1 2012 17
Comparative Analysis by Early Clinical Stage Development, H1 2012 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 19
Products under Development by Companies, H1 2012 20
Products under Investigation by Universities/Institutes, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 22
Eli Lilly and Company, H1 2012 23
Novartis AG, H1 2012 24
Pfizer Inc., H1 2012 25
Archer Biosciences, Inc, H1 2012 26
Assessment by Monotherapy Products, H1 2012 27
Assessment by Combination Products, H1 2012 28
Assessment by Stage and Route of Administration, H1 2012 30
Assessment by Molecule Type, H1 2012 32
Medulloblastoma Therapeutics – Drug Profile Updates 81
Medulloblastoma Therapeutics – Dormant Products 82
Medulloblastoma Therapeutics – Dormant Products (Contd..1) 83
List of Figures
Number of Products under Development for Medulloblastoma, H1 2012 10
Products under Development for Medulloblastoma – Comparative Analysis, H1 2012 11
Products under Development by Companies, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 16
Mid Clinical Stage Products, H1 2012 17
Early Clinical Stage Products, H1 2012 18
Pre-Clinical Stage Products, H1 2012 19
Assessment by Monotherapy Products, H1 2012 27
Assessment by Combination Products, H1 2012 28
Assessment by Route of Administration, H1 2012 29
Assessment by Stage and Route of Administration, H1 2012 30
Assessment by Molecule Type, H1 2012 31
Assessment by Stage and Molecule Type, H1 2012 32
[Tabellenverzeichnis ausblenden]